Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.430
+0.070 (2.08%)
At close: Mar 17, 2026, 4:00 PM EDT
3.380
-0.050 (-1.46%)
After-hours: Mar 17, 2026, 7:49 PM EDT

Prelude Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-99.5-127.17-121.83-115.44-111.69
Depreciation & Amortization
1.711.771.171.320.92
Stock-Based Compensation
11.9121.3525.6225.1420.93
Other Adjustments
1.16-3.05-1.544.312.69
Changes in Accounts Payable
-3.923.31-2.27-0.353.9
Changes in Accrued Expenses
-2.98-0.812.526.832.46
Changes in Unearned Revenue
35.53----
Changes in Other Operating Activities
-0.231.72-10.73-5.55-2.74
Operating Cash Flow
-56.3-102.89-107.06-83.73-83.53
Capital Expenditures
-0.07-0.76-3.51-3.02-2.32
Purchases of Investments
-100.87-52.69-221.63-119.22-261.48
Proceeds from Sale of Investments
154.39143.65190.5203.93-
Investing Cash Flow
53.4690.19-34.6581.69-263.8
Issuance of Common Stock
25.040.44136.410.82165.2
Net Common Stock Issued (Repurchased)
25.040.44136.410.82165.2
Other Financing Activities
-0.23-0.56-0.02--0.3
Financing Cash Flow
24.82-0.12136.40.82164.9
Net Cash Flow
21.97-12.82-5.31-1.22-182.44
Free Cash Flow
-56.37-103.65-110.58-86.75-85.85
FCF Margin
-464.32%-1480.74%---
Free Cash Flow Per Share
-0.73-1.37-1.83-1.83-1.86
Levered Free Cash Flow
-69.45-121.95-134.66-116.2-109.48
Unlevered Free Cash Flow
-74.51-134.49-145.1-124.3-111.52
Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q